WO2001069200A2 - Methodes de detection des differences entre acides nucleiques - Google Patents

Methodes de detection des differences entre acides nucleiques Download PDF

Info

Publication number
WO2001069200A2
WO2001069200A2 PCT/US2001/007858 US0107858W WO0169200A2 WO 2001069200 A2 WO2001069200 A2 WO 2001069200A2 US 0107858 W US0107858 W US 0107858W WO 0169200 A2 WO0169200 A2 WO 0169200A2
Authority
WO
WIPO (PCT)
Prior art keywords
holliday
nucleic acid
complex
difference
junction
Prior art date
Application number
PCT/US2001/007858
Other languages
English (en)
Other versions
WO2001069200A3 (fr
Inventor
Qinghong Yang
Wendy Yang
Alla Lishanski
Original Assignee
Freshgene, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Freshgene, Inc. filed Critical Freshgene, Inc.
Priority to CA002402483A priority Critical patent/CA2402483A1/fr
Priority to JP2001568034A priority patent/JP2003527119A/ja
Priority to AU4563401A priority patent/AU4563401A/xx
Priority to EP01918574A priority patent/EP1266202A4/fr
Priority to AU2001245634A priority patent/AU2001245634B2/en
Publication of WO2001069200A2 publication Critical patent/WO2001069200A2/fr
Publication of WO2001069200A3 publication Critical patent/WO2001069200A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism

Definitions

  • the present invention relates to the field of molecular biology, more particularly nucleic acid hybridization, Holliday junction formation and branch migration.
  • the invention provides methods and reagents for detecting the presence of a difference between two related nucleic acid sequences.
  • the difference is a mutation, such as a point mutation, deletion or insertion.
  • Practical applications of the invention include, but are not limited to, genotyping, discovery and detection of single nucleotide polymorphisms,, characterization and quantitation of polynucleotides, mutation rate detection, gene expression analysis.
  • the invention is capable of distinguishing between homozygous and heterozygous genetic variation.
  • nucleic acids to bind selectively and specifically to complementary nucleic acids has been exploited in the development of numerous nucleic acid hybridization techniques. Not only are such techniques useful for detecting complementarity and/or identity between nucleic acid sequences (e.g.: quantitating differential gene expression level such as Northern blots, Southern blots and gene expression chip/micro-arrays), but in some cases they are exploited to be used for detecting differences between related nucleic acid sequences.
  • quantitating differential gene expression level such as Northern blots, Southern blots and gene expression chip/micro-arrays
  • hybridization is stronger between two perfectly complementary DNA strands than that between two non-perfectly complementary DNA strands (including those that have either a single or multiple base-pair-mismatch between the two complementary strands), a single-base-pair difference is usually too small to render a high enough specificity for SNP scoring.
  • gene-expression chips and/or micro-arrays often have much better specificity/accuracy than SNP chips/micro-arrays due to the fact that the hybridization between specific cDNAs and their corresponding oligos/DNA fragments immobilized on the chip/micro-array is very specific. Such hybridization does not necessarily depend on a single-base pair difference between two nucleic acids.
  • the method disclosed herein addresses the problem by combining highly specific allele-specific holiday structure formation with nucleic acid hybridization techniques (e.g.: gene chip/micro-array).
  • nucleic acid hybridization techniques e.g.: gene chip/micro-array.
  • SNP chips/micro-arrays can achieve the same high level of specificity/accuracy as gene-expression chips/micro-arrays.
  • a single-stranded oligo that is completely (or partially) complementary to a specific part of single-stranded M13mpl8 viral DNA anneals to the viral DNA and form a partial duplex with either 1 (or 2) tail(s) at each end.
  • the partial duplex formed between the oligo and the M13mpl8 viral DNA can then form a four- way Holliday-like structure with an invading partial duplex with either 1 (or 2) complementary tails.
  • the four- way Holliday-like structure then undergoes branch migration in the direction away from the tail(s) (It can not branch migrate back towards the tail(s) due to energy barrier: breaking existing H-bonds without forming new ones).
  • a single (or multiple) base pair difference between the duplex part of oligo/M13mpl8 partial duplex and the duplex part of the invading partial duplex poses enough energy barrier (2 H-Bonds -> 0 H-bond) to impede the branch-migration and prevent the release of the annealed oligo, regardless of the presence or absence of Mg++.
  • a single base pair difference (substitution, deletion or insertion) between the duplex part of oligo/M13mpl8 partial duplex and the duplex part of the invading partial duplex poses enough energy barrier to impede the branch-migration and prevent the release of the annealed oligo ONLY in the presence of Mg++.
  • One method that has been proposed for detecting differences between related nucleic acid sequences involves forming a complex comprising a Holliday junction between the related sequences.
  • a complex comprising a Holliday junction between the related sequences.
  • each member of at least one pair of non-complementary strands within the complex is labeled.
  • the two labels generate a signal that is dependent upon the labels being in close proximity to one another. If there is a difference in the related nucleic acid sequences, the Holliday junction is stabilized, thus positioning the labels within close proximity to one another and thereby generating a signal.
  • the Holliday junction is not stabilized and the complex dissociates into duplexes, eliminating the close proximity between the two labels and attenuating the signal.
  • a determination is made whether a stabilized complex is formed, the presence thereof indicating the existence of a difference between the related sequences.
  • One problem with the above-identified method of detecting differences between related nucleic acid sequences is that it normally requires the use of labeled PCR primers to generate the labeled nucleic acid strands required for detection of the Holliday junction complex.
  • the use of labeled primers can be problematic owing to the concentration of primer that must be used and the ensuing interference that occurs in the presence of high levels of labeled primers. This is a significant disadvantage, since one of the primary practical applications of the methodology is for the analysis of genomic DNA.
  • the present invention addresses the problems associated with the use of labeled polynucleotides and primers by providing novel methods and reagents for the rapid and efficient identification of differences between related nucleic acid sequences. As such, the invention constitutes a highly desirable and practical addition to fields of endeavor including molecular biology and medicine.
  • the present invention provides methods for detecting the presence or absence of a difference between two related nucleic acid sequences.
  • the methods achieve sensitivities great enough to detect the presence of any difference between the nucleic acids, even single nucleotide polymorphisms.
  • a target nucleic acid and a reference nucleic acid are contacted under conditions in which they are capable of forming a four- way nucleic acid complex with a branch structure that is capable of migration. Under the contact conditions, if the reference nucleic acid and target nucleic acid are identical, branch migration is capable of going to completion resulting in complete strand exchange. If the reference nucleic acid and target nucleic acid are different, branch migration does not go to completion, resulting in a stable four-way complex.
  • Detection of the stable four- way complex identifies the presence of a difference between the nucleic acids.
  • a stable four- way complex can be detected with molecules that specifically bind such complexes, by gel electrophoresis or by specific isolation of the stable four-way complex.
  • the present invention provides a method for detecting the presence of a difference between two related nucleic acid sequences.
  • the method involves forming a four-way complex comprising both of the nucleic acid sequences in duplex form, wherein the nucleic acids within the four-way complex are either not labeled or one of the four nucleic acid strands forming the four-way complex has a label, subjecting the four-way complex to conditions allowing branch migration to occur wherein, if a difference between the two related nucleic acid sequences is present, branch migration in said four-way complex ceases and the four-way complex continues to exist as a stable four- way complex; and wherein, if no difference between the two related nucleic acid sequences is present, branch migration in the four-way complex continues until complete strand exchange occurs and the four-way complex resolves into two duplex nucleic acids, subjecting said four-way complex or its resolved duplex products after branch migration to conditions allowing the specific binding of reagent(s) to said four-way complex and the binding of said reagent(s) to said four- way complex produces a detectable signal, and detecting the signal produced upon
  • the present invention provides a method for detecting the presence of a difference between two related nucleic acid sequences.
  • the method involves forming a four- way complex comprising both of the nucleic acid sequences in duplex form, wherein the nucleic acids within the four-way complex are either not labeled or one or more of the four nucleic acid strands forming the four- way complex has a label, subjecting the four-way complex to conditions allowing branch migration to occur wherein, if a difference between the two related nucleic acid sequences is present, branch migration in said four-way complex ceases and the four-way complex continues to exist as a stable four-way complex; and wherein, if no difference between the two related nucleic acid sequences is present, branch migration in the four-way complex continues until complete strand exchange occurs and the four- way complex resolves into two duplex nucleic acids, subjecting said four-way complex or its resolved duplex products after branch migration to conditions allowing the separation of the four-way DNA complex (Holliday structure
  • FIG. 1 provides a schematic diagram of an embodiment in accordance with the present invention for detecting any difference between two related nucleic acid sequences using PCR wherein absence of any difference between the two related sequences leads to complete branch migration and the resolution of the Holliday junction complexes;
  • FIG. 2 provides a schematic diagram of an embodiment in accordance with the present invention for detecting any difference between two related nucleic acid sequences using PCR wherein presence of any difference between the two related sequences blocks branch migration and leads to the formation of stable Holliday junction complexes;
  • FIG. 4 provides a schematic diagram of showing another way of using Holliday junction specifically binding protein(s) for detecting a difference between two related nucleic acid sequences wherein a mutation is present in one of the two related sequences and branch migration is stopped, leading to the formation of stable Holliday junction complexes that can be detected by using labeled Holliday junction specifically binding protein(s);
  • FIG. 5 provides a schematic diagram of a method of genotyping a target DNA
  • FIG. 7 is a schematic diagram of an embodiment in accordance with the present invention for determining the genotypes of diploid genomic DNA samples at particular SNP positions by using PCR;
  • FIG. 8 A provides a the results of a typical gel electrophoresis experiment wherein stable Holliday structures are detected
  • FIG. 8B provides the results of a typical gel electrophoresis experiment wherein nucleotide differences withinin several pairs are detected
  • FIG. 9A illustrates a mobility shift of a stable Holliday structure upon protein binding
  • FIG. 9B illustrates specific binding of a stable Holliday structure by RuvA
  • FIG. 9C illustrates specific binding of a stable Holliday structure by RuvA, a mutant
  • FIG. 10 illustrates the specific interaction of a stable Holliday structure with both RuvA and RuvC.
  • TABLE 1 illustrates an exemplary method for determining the genotypes of diploid genomic DNA samples using PCR.
  • the present invention overcomes these and other limitations by providing novel methods for the detection of a difference between nucleic acids.
  • the methods of the present invention display improved accuracy and efficiency when compared to previous methods for detecting a difference between two nucleic acids.
  • nucleic acids comprising specific nucleobase sequences are the conventional one-letter abbreviations.
  • the naturally occurring encoding nucleobases are abbreviated as follows: adenine (A), guanine (G), cytosine (C), thymine (T) and uracil (U).
  • A adenine
  • G guanine
  • C cytosine
  • T thymine
  • U uracil
  • nucleic acid sequences that are represented as a series of one-letter abbreviations are presented in the 5' -> 3' direction.
  • nucleic acid and “polynucleotide” are interchangeable and refer to any nucleic acid, whether composed of deoxyribonucleosides or ribonucleosides, and whether composed of phosphodiester linkages or modified linkages such as phosphotriester, phosphoramidate, siloxane, carbonate, carboxymethylester, acetamidate, carbamate, thioether, bridged phosphoramidate, bridged methylene phosphonate, phosphorothioate, methylphosphonate, phosphorodithioate, bridged phosphorothioate or sulfone linkages, and combinations of such linkages.
  • phosphodiester linkages or modified linkages such as phosphotriester, phosphoramidate, siloxane, carbonate, carboxymethylester, acetamidate, carbamate, thioether, bridged phosphoramidate, bridged methylene phosphonate, phosphorothioate, methylphosphon
  • nucleic acid, polynucleotide, and nucleotide also specifically include nucleic acids composed of bases other than the five biologically occurring bases (adenine, guanine, thymine, cytosine and uracil).
  • a polynucleotide of the invention might contain at least one modified base moiety which is selected from the group including but not limited to 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl)uracil, 5- carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1- methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5- methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylque
  • the polynucleotide can be from a human or non-human mammal, or any other organism, or derived from any recombinant source, synthesized in vitro or by chemical synthesis.
  • the nucleotide may be DNA, RNA, cDNA, DNA-RNA, hybrid or any mixture of the same, and may exist in a double-stranded, single-stranded or partially double-stranded form.
  • the nucleic acids of the invention include both nucleic acids and fragments thereof, in purified or unpurified forms, including genes, chromosomes, plasmids, the genomes of biological material such as microorganisms, e.g., bacteria, yeasts, viruses, viroids, molds, fungi, plants, animals, humans, and the like.
  • the nucleic acid can be only a minor fraction of a complex mixture such as a biological sample.
  • the nucleic acid can be obtained from a biological sample by procedures well known in the art.
  • a polynucleotide of the present invention can be derivitized or modified, for example, for the purpose of detection, by biotinylation, amine modifictaion, alkylation, or other like modification.
  • the invention can employ nucleic acids having modified internucleoside linkages.
  • methods for synthesizing nucleic acids containing phosphonate phosphorothioate, phosphorodithioate, phosphoramidate methoxyethyl phosphoramidate, formacetal, thioformacetal, diisopropylsilyl, acetamidate, carbamate, dimethylene-sulfide, dimethylene- sulfoxide, dimethylene-sulfone, 2'-O-alkyl, and 2'-deoxy-2'-fluoro phosphorothioate internucleoside linkages are well known in the art (see Uhlman et al, 1990, Chem. Rev.
  • oligonucleotide refers to a relatively short, single stranded polynucleotide, usually of synthetic origin.
  • An oligonucleotide typically comprises a sequence that is 8 to 100 nucleotides, preferably, 20 to 80 nucleotides, and more preferably, 30 to 60 nucleotides in length.
  • Various techniques can be employed for preparing an oligonucleotide utilized in the present invention. Such oligonucleotide can be obtained by biological synthesis or by chemical synthesis. For short sequences (up to about 100 nucleotides) chemical synthesis will frequently be more economical as compared to the biological synthesis.
  • chemical synthesis provides a convenient way of incorporating low molecular weight compounds and/or modified bases during the synthesis step. Furthermore, chemical synthesis is very flexible in the choice of length and region of the target polynucleotide binding sequence.
  • the oligonucleotide can be synthesized by standard methods such as those used in commercial automated nucleic acid synthesizers. Chemical synthesis of DNA on a suitably modified glass or resin can result in DNA covalently attached to the surface. This may offer advantages in washing and sample handling. For longer sequences standard replication methods employed in molecular biology can be used such as the use of Ml 3 for single stranded DNA as described by J. Messing (1983) Methods Enzymol, 101, 20-78.
  • oligonucleotide synthesis include phosphotriester and phosphodiester methods (Narang, et al. (1979) Meth. Enzymol 68: 90) and synthesis on a support (Beaucage, et al. (1-981) Tetrahedron Letters 22: 1859- 1862) as well as phosphoramidate technique, Caruthers, M. H., et al., "Methods in Enzymology," Vol. 154, pp. 287-314 (1988), and others described in “Synthesis and Applications of DNA and RNA," S. A. Narang, editor, Academic Press, New York, 1987, and the references contained therein.
  • oligonucleotide “primer” can be employed in a chain extension on a polynucleotide template such as in, for example, an amplification of a nucleic acid.
  • the oligonucleotide primer is usually a synthetic oligonucleotide that is single stranded, containing a hybridizable sequence at its 3 '-end that is capable of hybridizing with a defined sequence of the target or reference polynucleotide.
  • the hybridizable sequence of the oligonucleotide primer has at least 90%, preferably 95%, most preferably 100%, complementarity to a defined sequence or primer binding site.
  • the number of nucleotides in the hybridizable sequence of an oligonucleotide primer should be such that stringency conditions used to hybridize the oligonucleotide primer will prevent excessive random nonspecific hybridization.
  • the number of nucleotides in the hybridizable sequence of the oligonucleotide primer will be at least ten nucleotides, preferably at least 15 nucleotides and, preferably 20 to 50, nucleotides.
  • the primer may have a sequence at its 5'- end that does not hybridize to the target or reference polynucleotides that can have 1 to 60 nucleotides, 5 to 30 nucleotides or, preferably, 8 to 30 nucleotides.
  • sample refers to a material suspected of containing a nucleic acid of interest.
  • samples include biological fluids such as blood, serum, plasma, sputum, lymphatic fluid, semen, vaginal mucus, feces, urine, spinal fluid, and the like; biological tissue such as hair and skin; and so forth.
  • Other samples include cell cultures and the like, plants, food, forensic samples such as paper, fabrics and scrapings, water, sewage, medicinals, etc.
  • the sample may be pretreated with reagents to liquefy the sample and/or release the nucleic acids from binding substances. Such pretreatments are well known in the art.
  • amplification refers to any method that results in the formation of one or more copies of a nucleic acid, where preferably the amplification is exponential.
  • One such method for enzymatic amplification of specific sequences of DNA is known as the polymerase chain reaction (PCR), as described by Saiki, et al, (1986) Science, 230: 1350-54.
  • Primers used in PCR can vary in length from about 10 to 50 or more nucleotides, and are typically selected to be at least about 15 nucleotides to ensure sufficient specificity.
  • the double stranded fragment that is produced is called an "amplicon” and may vary in length form as few as about 30 nucleotides to 20,000 or more.
  • chain extension refers to the extension of a 3'-end of a polynucleotide by the addition of nucleotides or bases.
  • Chain extension relevant to the present invention is generally template dependent, that is, the appended nucleotides are determined by the sequence of a template nucleic acid to which the extending chain is hybridized.
  • the chain extension product sequence that is produced is complementary to the template sequence.
  • chain extension is enzyme catalyzed, preferably, in the present invention, by a thermostable DNA polymerase, such as the enzymes derived from Thermis acquaticus (the Taq polymerase), Thermococcus litoralis, and Pyrococcus furiosis.
  • Brain migration conditions are conditions under which migration of the Holliday junction branch can proceed along the component polynucleotide strands. Normally in the practice of the invention, conditions are chosen such that migration will proceed only if strand exchange does not result in a mismatch, wherein the formation of a single base mismatch will impede branch migration, resulting in a stabilized Holliday junction or Holliday junction complex. Appropriate conditions can be found, for example, in Panyutin and Hsieh, (1993) J. Mol. Biol, 230:413-24. In certain applications the conditions will have to be modified due to the nature of the particular polynucleotides involved. Such modifications are readily discernible by one of skill in the art without undue experimentation.
  • a "stabilized" Holliday junction is a junction where a mismatch has stalled branch migration to an extent sufficient that the stabilized Holliday junction is detectable and distinguishable from the duplex DNA that would be released from a Holliday junction involving identical sequences owing to branch migration.
  • a Holliday junction comprising "complex” refers to a complex of four nucleic acid strands associated through a Holliday junction, which can be inhibited from dissociation into two double stranded sequences by a difference in the sequences and their complements.
  • Two nucleic acid sequences are "related" when they are either (1) identical to each other, or (2) would be identical were it not for some difference in sequence that distinguishes the two nucleic acid sequences from each other.
  • the difference can be a substitution, deletion or insertion of any single nucleotide or a series of nucleotides within a sequence. . Such difference is referred to herein as the "difference between two related nucleic acid sequences.”
  • related nucleic acid sequences differ from each other by a single nucleotide.
  • Related nucleic acid sequences typically contain at least 15 identical nucleotides at each end but have different lengths or have intervening sequences that differ by at least one nucleotide.
  • mutant refers to a change in the sequence of nucleotides of a normally conserved nucleic acid sequence resulting in the formation of a mutant as differentiated from the normal (unaltered) or wild type sequence. Mutations can generally be divided into two general classes, namely, base-pair substitutions and frame-shift mutations. The latter entail the insertion or deletion of one to several nucleotide pairs. A difference of one nucleotide can be significant as to phenotypic normality or abnormality as in the case of, for example, sickle cell anemia.
  • a “duplex” is a double stranded nucleic acid sequence comprising two complementary sequences annealed to one another.
  • a “partial duplex” is a double stranded nucleic acid sequence wherein a section of one of the strands is complementary to the other strand and can anneal to form a partial duplex, but the full lengths of the strands are not complementary, resulting in a single-stranded polynucleotide tail at at least one end of the partial duplex.
  • hybridization binding
  • annealing in the context of polynucleotide sequences, are used interchangeably herein.
  • the ability of two nucleotide sequences to hybridize with each other is based on the degree of complementarity of the two nucleotide sequences, which in turn is based on the fraction of matched complementary nucleotide pairs.
  • the more nucleotidesin a given sequence that are complementary to another sequence the more stringent the conditions can be for hybridization and the more specific will be the binding of the two sequences.
  • Increased stringency is typically achieved by elevating the temperature, increasing the ratio of cosolvents, lowering the salt concentration, and other such methods well known in the field.
  • Two sequences are "complementary" when the sequence of one can bind to the sequence of the other in an anti-parallel sense wherein the 3 '-end of each sequence binds to the 5 '-end of the other sequence and each A, T(U), G, and C of one sequence is then aligned with a T(U), A, C, and G, respectively, of the other sequence.
  • a "small organic molecule” is a compound of molecular weight less than about 1500, preferably 100 to 1000, more preferably 300 to 600 such as biotin, digoxigenin, fluorescein, rhodamine and other dyes, tetracycline and other protein binding molecules, and haptens, etc.
  • the small organic molecule can provide a means for attachment of a nucleotide sequence to a label or to a support.
  • the present invention is universal and permits detection of any difference in two related nucleic acid sequences, regardless of whether such difference is known a priori. Such differences include any mutation within a nucleic acid sequence, e.g..a single or multiple base substitution or polymorphism, a deletion or an insertion.
  • Methods of the invention are rapid, convenient, and amenable to automation, and can be conducted in a homogeneous or heterogeneous format. They are ideally suited for rapid mutation pre- screening and genotyping, particularly involving the identification of single nucleotide polymorphisms (SNPs).
  • SNPs single nucleotide polymorphisms
  • the disclosed methods are sensitive and quantitative, and are particularly amenable to application with polymerase chain reaction (PCR).
  • the present invention provides methods and reagents useful for the detection of a difference between two related nucleic acid sequences by determining whether constructs comprising the sequences are capable of forming a stabilized Holliday junction.
  • the present invention provides methods and reagents for generating such constructs for use in the practice of the invention, and methods and reagents useful for stabilizing and detecting Holliday junctions.
  • the stabilized Holliday junction is detected by means of one or more binding proteins capable of specifically binding a Holliday junction.
  • the invention provides a novel methodologies for detecting a difference between two polynucleotide sequences by means of the formation of a stabilized Holliday structure involving polynucleotide constructs comprising the sequences, as illustrated in FIG. 1.
  • the reference sequence is typically a polynucleotide of substantially known sequence
  • the target sequence is a related sequence for which it is desired to detect whether there is a difference relative to the reference sequence.
  • sequences are related in the sense that the sequences are either identical, or would be identical if not for some difference between the two sequences.
  • the difference is a substitution, deletion or insertion variation or mutation, such as but not limited to a single nucleotide polymorphism (SNP).
  • SNP single nucleotide polymorphism
  • the target sequence and the reference sequence are prepared as a pair of sequences that are capable of forming a partial duplex according to the methods described in detail below.
  • a typical partial duplex A' is illustrated in FIG. 1.
  • Partial duplex A' comprises a complementary duplex region and one or more tail regions.
  • a complementary duplex region comprises a target sequence or a reference sequence annealed to its complement.
  • Other examples of partial duplexes are illustrated as A", B' and B".
  • one tail region comprises the oligonucleotide tails Tl and T2 ⁇
  • a second tail region comprises the oligonucleotide tails T3' and T4.
  • Tail Tl, T2', T3' and/or T4 can be linked to the target sequence via any linkage known to those of skill in the art for linking polynucleotides. They can be linked directly via a covalent bond or via a linker.
  • the linker can be a polynucleotide or any other linker known to those of skill in the art.
  • tail Tl and/or T3' is linked to the target sequence directly via a phosphodiester linkage.
  • tail Tl, T2, T3, T4, Tl', T2', T3' and/or T4' can be linked to a target sequence or a reference sequence.
  • a partial duplex has one tail region.
  • partial duplex A' has one tail region when Tl is 0 bp in length and T2' is 0 bp in length while T3' > 0 bp and T4 > 0 bp (or, alternatively, when Tl > 0 bp and T2' > 0 bp while T3' and T4 are both 0 bp in length).
  • a partial duplex has two tail regions.
  • the partial duplex illustrated in FIG. 1 has two tail regions when Tl, T2 ? , T3' and T4 are all greater than 0 bp in length. Tails Tl, T2', T3' and T4 are preferably 5bp-500bp and more preferably 5bp-55bp.
  • All four tails are comprised of sequences that unrelated to each other and to the template DNA, or alternatively, one of the pair of polynucleotide tails at each terminus of the partial duplexes (T1/T2' or T3VT4) can be template DNA sequences.
  • a tail is capable of hybridizing with another sequence that complements the tail without interference from the target sequence, the reference sequence or from other tails.
  • partial duplexes A' and B illustrated in FIG. 1, are capable of forming a four-way structure under the appropriate conditions.
  • partial duplex A' comprises the tails Tl, T2', T3', and T4.
  • Another partial duplex B M comprises the tails Tl', T2, T3 and T4 ⁇
  • Each pair of polynucleotide tails at each end of the partial duplexes e.g., T1/T2', T2/T1', T37T4, T3/T4' are not complementary and will not anneal to one another under the applicable conditions.
  • tail T3' at the right end of partial duplex A' is complementary to, and hence can hybridize with, tail T3 at the right end of partial duplex B.
  • Tail T4 at the right end of partial duplex A' is complementary to, and hence can hybridize with, tail T4' at the right end of partial duplex B.
  • Tail Tl at the left end of partial duplex A' is complementary to, and hence can hybridize with, tail Tl" at the left end of partial duplex B.
  • Tail T2' at the left end of partial duplex A' is complementary to, and hence can hybridize with, tail T2 at the left end of partial duplex B".
  • the partial duplexes described above can be prepared by any method known to those of skill in the art for the preparation of polynucleotides or nucleic acids.
  • the partial duplexes can be prepared by standard recombinant, synthetic or PCR techniques, or a combination thereof.
  • the partial duplexes, or portions thereof such as the target or reference sequence can be isolated from natural sources. Exemplary methods of preparing sequences that are capable of forming partial duplexes are described in U.S. Patent No. 6,013,439, which is hereby incorporated by reference in its entirety.
  • FIG. 1 illustrates the preparation of partial duplexes A', A", B' and B" by PCR.
  • Partial duplexes such as A' and B" can be used to detect a difference between a target sequence and a reference sequence.
  • A can be a target sequence and B a reference sequence, or vice versa.
  • duplex A and B are amplified, either separately or jointly, by standard PCR using a common set of primers made up of one or more forward primers and two reverse primers Rl & R2.
  • forward primer FI or forward primer F2 can be used in the PCR reaction. If forward primer FI is used, duplexes with Tl/Tl' tails will be generated such as Al.
  • forward primer F2 duplexes with T2/T2' tails will be generated such as A2.
  • Two forward primers can also be used to generate partial duplexes at the end corresponding to the forward primer. For instance, using forward primers FI and F2 in the same PCR reaction generates sequences that can be used to produce partial duplexes A' and A".
  • a forward primer with no tails can be used to generate a duplex with no tails at the end corresponding to the forward primer.
  • the primers need not be labeled, but that in certain applications the labeling of one or more primers can be desirable.
  • the distance between the binding sites for the forward and reverse primers is at least 1 base pair, preferably in the range of 1 - 600 base pairs or 5 - 600 base pairs, more preferably in the range of 5 - 100 base pairs, depending on the desired purpose of the application and the nature of the polynucleotide of interest.
  • PCR amplification according to the invention involves temperature cycling to denature duplexes, oligonucleotide primer annealing, and primer extension by thermal- stable template dependent nucleotide polymerase.
  • the temperatures for the present method for the amplification by PCR generally range from about 50°C to 100°C, more usually from about 60°C to 95°C. Relatively low temperatures of from about 50°C to 80°C are employed for hybridization steps, while denaturation is carried out at a temperature of from about 80°C to 100°C and extension is carried out at a temperature of from about 70°C to 80°C, usually about 72°C to 74°C.
  • the time period for conducting the method is from about 10 seconds to 10 minutes per cycle and any number of cycles can be used from one to as high as 60 or more, usually 10 to 50, frequently 20 to 45.
  • PCR protocols are known in the art and can be found, for example, in Sambrook et al., Molecular Cloning: A Laboratory Manual, 2 nd ed., Cold Spring Harbor Laboratory Press, New York (1989), or arrived at by the skilled artisan without undue experimentation.
  • the PCR amplification employs convergent oligonucleotide primers designed to be complementary to and anneal to sequences flanking the area of the nucleic acids to be amplified.
  • the primers are designed such that the 3' portion is at least 90%, preferably 95%, and most preferably 100% complementary to a portion of the strand to be amplified.
  • the complementary portion of the primer should be long enough to hybridize selectively to the target or reference sequence under the primer annealing conditions employed for the reaction.
  • the number of nucleotides in the hybridizable sequence of the primer will be at least 10, preferably at least 15 nucleotides, and more preferably 20 to 50 nucleotides in length.
  • the primer is complementary to the target sequence, such as for example the F primer in FIG. 1.
  • the 5' end of the primer is not complementary to the target, in which case this non-complementary sequence will be incorporated at the end of the resulting amplicon.
  • the non-complementary end can have 1 to 60 or more nucleotides, 5 to 30 nucleotides or, preferably, 8 to 30 nucleotides. It is by means of such primers that the oligonucleotide tails at the end of the partial duplexes are generated.
  • Such primers can also be used to generate amplicon intermediates capable of recognition by a universal primer for the production of the partial duplexes of the invention.
  • the concentration of oligonucleotide primers used in the PCR amplification will be at least as great as the number of copies desired and will usually be in the range of 1 nM to 1 mM, preferably 100 nM to 110 ⁇ M.
  • concentration of oligonucleotide primers used in the PCR amplification will be at least as great as the number of copies desired and will usually be in the range of 1 nM to 1 mM, preferably 100 nM to 110 ⁇ M.
  • For the amplification of genomic DNA about 500nM-1000nM for the forward primers and -250 ⁇ M - 500 ⁇ M for each of the two reverse primers is preferred, i.e, similar to the conditions used to amplify an STS (sequence tagged site).
  • lower primer concentrations are sufficient, for example about 25 nM-250 nM.
  • forward primer F The entire sequence of the forward primer F hybridizes with the template DNA, i.e., both A and B.
  • Fl has a 5 '-end portion (Tl) that does or does not hybridize with the template DNA.
  • F2 has a 5 '-end portion (T2) that does or does not hybridize with the template DNA.
  • Rl has a 5'-end portion (T3) that does not hybridize with the template DNA.
  • R2 has a 5 '-end portion (T4) that is not complementary to and hence does not hybridize with the template DNA.
  • T3 is not related with T4, i.e., the complementary strand of T3 (T3') is not complementary to T4 and the complementary strand of T4 (T4') is not complementary to T3.
  • T4' will not hybridize with T3 under the conditions employed in the method.
  • Multiple rounds of PCR amplification will result in the formation of a number of DNA products, including the component strands of the four tailed partial duplexes A', A", B', B" (FIG. 1).
  • the tailed duplexes are formed by adjusting the temperature of the solution so that the component strands can hybridize to form the desired partial duplexes. Note that a number of other duplexes will also be formed. These unintended products generally do not pose a problem because a sufficient number of partial duplexes are formed under the conditions described above.
  • Each tailed partial duplex A' is comprised of a duplex of two complementary nucleic acid strands of duplex A and, at one end of the duplex, two non-complementary oligonucleotide tails T3' and T4.
  • Each tailed partial duplex A" is comprised of a duplex of two complementary nucleic acid strands of duplex A and, at one end of the duplex, two non-complementary oligonucleotide tails T4' and T3.
  • partial duplex A" can have either zero, one or two tails at the other end of the partial duplex (see above).
  • Each tailed partial duplex B' is comprised of a duplex of two complementary nucleic acid strands of duplex B and, at one end of the duplex, two non-complementary oligonucleotide tails T3' and T4.
  • partial duplex B' can have either zero/one/two tails at the other end of the partial duplex (see above).
  • Each tailed partial duplex B" is comprised of a duplex of two complementary nucleic acid strands of duplex B and, at one end of the duplex, two non-complementary oligonucleotides T4' and T3.
  • partial duplex B" can have either zero, one or two tails at the other end of the partial duplex (see above).
  • a and B can be achieved in separate reactions using primers Fl/Rl or F2/R2, as depicted in FIG. 1.
  • the resulting tailed amplification products could then be combined under the appropriate conditions to form partial duplexes A', A", B' and B" (FIG. 1).
  • PCR amplification products Al & Bl by using Fl/Rl, see FIG. 1
  • A2&B2 by using F2/R2, see FIG. 1
  • a and B can be achieved in separate reactions using primers Fl/Rl or F2/R2, as depicted in FIG. 1.
  • the resulting tailed amplification products could then be combined under the appropriate conditions to form partial duplexes A', A", B' and B" (see FIG. 1).
  • a and B can be achieved in separate reactions using primers F, Rl and R2, and the resulting tailed amplification products could then be combined under the appropriate conditions to form partial duplexes A', A", B' and B".
  • a and B could initially be amplified using F and only one of the R primers
  • partial duplexes (A', A", B', B") comprising sequences A and B are brought into contact under conditions where the complementary tails can anneal to one another, thereby initiating the formation of a four- stranded complex (Holliday junction), as depicted in FIG. 1.
  • the resulting complexes CI, C2, C3, C4 are subjected to conditions where branch migration can occur.
  • Branch migration is restricted from proceeding in the direction of the tails, because the tails on a given partial duplex are not complementary to one another, e.g., Tl is not complementary to T2'. However, branch migration can occur in the other direction to the extent that the reference and target sequences are the same.
  • the right terminus of the tailed partial duplex A' has, as the end part of each strand, sequence T4 and T3', respectively, that are complementary to T4' and T3, respectively, that are tails at the right terminus of B" and are not complementary to each other.
  • T4 and T3' sequence complementary to T4' and T3, respectively, that are tails at the right terminus of B" and are not complementary to each other.
  • two four-way Holliday junction comprising partial duplex A' and B" can form.
  • One can form as the result of the hybridization of tail Tl of A' with tail Tl' of B" and hybridization of tail T2' of A' with tail T2 of B".
  • tail T3' of A' with tail T3 of B Another can form as a result of the hybridization of tail T3' of A' with tail T3 of B" and the hybridization of tail T4 of A' with tail T4' of B".
  • two more four- way Holliday junction complexes C3 and C4 from partial duplexes A" and B' One can form when tail Tl' of A" hybridizes with tail Tl of B' and when tail T2 of A" hybridizes with tail T2' of B'.
  • partial duplexes A', A", B' and B M can form concatemers.
  • three partial duplexes B", A' and a second partial duplex B" can form a concatamer with two Holliday junctions.
  • concatemers do not prevent the detection of differences between sequence A and sequence B. If sequences A and B are identical, then migration of both Holliday structure branches in the B" - A' - B" should go to completion resulting in resolution of the entire concatemer into two duplexes. If there is a difference between sequences A and B, then both Holliday structures will be stabilized. Detection of the stabilized Holliday structures will indicate the difference between . sequences A and B.
  • the Holliday junction complexes CI, C2, C3 and C4 are subject to branch migration conditions wherein, because tails Tl and T2 and tails T3 and T4 are different, the branch migration can only proceed away from the tails whose hybridization initiates four- way Holliday complex formation. If there is no mismatch between A and B, the branch migration of complex CI, C2, C3 and C4 can proceed away from the tail all the way to the other end of the partial duplexes. As a result, each of the four Holliday complexes CI, C2, C3 and C4 resolve into duplexes (FIG. 1).
  • branch migration is conducted in the presence of an ion such as Mg* "1" , which enhances the tendency of a mismatch to impede spontaneous DNA migration and hence stabilizes Holliday junction complexes involving such a mismatch.
  • Mg* "1" an ion such as Mg* "1" , which enhances the tendency of a mismatch to impede spontaneous DNA migration and hence stabilizes Holliday junction complexes involving such a mismatch.
  • a preferred concentration range for Mg "1""1" is 1 to 10 mM.
  • stabilization can be achieved by means of other ions, particularly divalent cations such Mh" " or Ca ⁇ , or by a suitable combination of ions.
  • branch migration is achieved by incubation at 65°C for about 20-120 minutes in buffer containing 4mM MgCl 2 , 50mM KC1, lOmM Tris-HCl, PH 8.3 .
  • a description of branch migration conditions suitable for the formation of stabilized Holliday junction as a consequence of a single base mismatch can be found, for example, in Panyutin and Hsieh, (1993) J. Mol. Biol, 230:413- 24, which is hereby incorporated by reference in its entirety.
  • the stabilized Holliday junction indicative of a difference between nucleic acids A and B is detected by any of the means described below.
  • a stabilized Holliday junction can be detected by a molecule or molecules capable of specifically recognizing and binding a Holliday junction, .
  • a molecule or molecules with specificity for a Holliday structure is used to detect the presence of a stabilized Holliday structure and thereby the presence of a difference between polynucleotide sequence A and polynucleotide sequence B.
  • the presence of a Holliday structure can be detected with any molecule or molecules known to those of skill in the art to specifically bind Holliday structures.
  • a protein or proteins is used to bind and detect the formation of a stabilized Holliday junction. Many proteins from various organisms have been shown specifically bind to Holliday junctions. Those proteins include but are not limited to: RuvA, RuvC, RuvB, RusA, RuvG of E.
  • proteins/mutants derived from RuvA, RuvC, RuvB, RusA, RuvG include homologs (including functional homologs) of RuvA, RuvC, RuvB, RusA, RuvG from various other organisms, such as the homologs of RuvA, RuvC, RuvB, RusA, and RuvG derived from mammals, Ccel and spCcel from yeast, Hjc from Pyrococcus furiosusa, and various other resolvases and recombinases that can specifically bind to Holliday structures.
  • thermostable proteins are used to detect the presence of a Holliday structure.
  • Such thermostable proteins include thermostable homologs of RuvA, RuvC, RuvB, RusA, and RuvG that are derived from thermophihc organisms - organisms selected from the group consisting of Thermus aquaticus, Thermusflavus, Thermus thermophilus and other thermophihc organisms known to those of skill in the art.
  • Hjc from Pyrococcus furiosusa is one good example of an appropriate thermostable protein with specificity for Holliday structures.
  • coli RuvC provides evidence for conserved mechanism of homologous recombination in Bacteria, Eukarya, and Archaea. Proc ⁇ atl Acad Sci U S A. 96(16):8873-8; Komori K, et al. 2000. Mutational analysis of the Pyrococcus furiosus Holliday junction resolvase Hjc revealed functionally important residues for dimer formation, junction D ⁇ A binding and cleavage activities. J Biol Chem.(September/2000 issue); Sharpies GJ, et al. 1999.
  • Holliday junction processing in bacteria insight from the evolutionary conservation of RuvABC, RecG, and RusA. J bacteriol 181(8);5543-50; Sharpies GJ, et al. 1993. An E. coli RuvC mutant defective in cleavage of synthetic Holliday junctions. Nucleic Acid Research, 21(15): 3359-64. Proteins specifically bound to a Holliday structure can be detected by methods known to those of skill in the art for detecting and/or visualizing proteins. In fact, one advantage of the instant invention is that is allows for the detection of stable Holliday junctions without the use of labeled nucleic acids.
  • At least one Holliday junction-specific binding protein i.e., a protein capable of selectively recognizing and binding a Holliday junction
  • a protein capable of selectively recognizing and binding a Holliday junction is labeled with at least one label and subjected to conditions that allow said protein(s) to bind to a stable Holliday junction such as complex CI , C2, C3 and/or C4.
  • the binding of said proteins to the Holliday junction produces some signal(s) that can be detected, preferably in a quantitative way.
  • Said signals can be used as indicators for the presence and quantity of stable Holliday junctions, and in turn, as indicators for the presence and quantity/ratio of mismatched DNA in DNA polymo ⁇ hism analysis.
  • the instant invention employs at least one labeled protein to detect the Holliday junction.
  • the label can be endogenous to the protein, e.g., the natural fluorescence of a protein resulting from the fluorescence of amino acids such as tryptophan, tyrosine, or phenylalanine, or a protein side-chain capable of reacting in a detectable manner.
  • the label can be attached to the protein, either during translation or post- translationally.
  • Suitable labels include, but are not limited to, fluorescent molecules (including, for example, fluorescein, rhodamine, and fluorescent proteins and peptides such as GFP and GFP variants and analogs), radioactive groups, solid surfaces, oligonucleotides, enzymes, dyes, chemiluminiscent groups, coenzymes, enzyme substrates, ligands, receptors and small organic molecules.
  • fluorescent molecules including, for example, fluorescein, rhodamine, and fluorescent proteins and peptides such as GFP and GFP variants and analogs
  • radioactive groups include, but are not limited to, fluorescent molecules (including, for example, fluorescein, rhodamine, and fluorescent proteins and peptides such as GFP and GFP variants and analogs), radioactive groups, solid surfaces, oligonucleotides, enzymes, dyes, chemiluminiscent groups, coenzymes, enzyme substrates, ligands, receptors and small organic molecules.
  • two or more proteins can be used to detect a stabilized Holliday junction.
  • the two proteins can be the same protein or two different proteins, or domains or subunits of a single protein.
  • the two or more proteins can associate to form a dimer or higher order oligomer, and in some embodiments oligomerization is dependent upon binding to a Holliday junction.
  • the two proteins are labeled with different labels and Holliday- junction-dependent complex formation between these two proteins causes the association of the two labels.
  • the association of the two labels can be used as an indicator for the presence of stable Holliday junctions (FIG. 3).
  • RuvA and RuvC cannot form a RuvC-RuvA complex by themselves in the absence of Holliday junction.
  • both RuvA and RuvC can bind to a Holliday junction simultaneously and form a RuvA-RuvC-Holliday junction complex.
  • Both RuvA and RuvC, as well as many RuvC mutants, have been cloned, over-expressed and purified.
  • RuvA and RuvC are each fused with a different fluorophores capable of serving as a donor/acceptor pair for intermolecular fluorescence resonance energy transfer (FRET).
  • FRET intermolecular fluorescence resonance energy transfer
  • FRET Fluorescence resonance energy transfer between blue-emitting and red-shifted excitation derivatives of green fluorescente protein. Gene 173:13-7; and Furey WS, et al. 1998. Use of fluorescence energy transfer to investigate the conformation of DNA substrates to the Klenow fragment.
  • the invention preferably employs a RuvC mutant that lacks the wild-type form of the enzyme's Holliday junction-specific endonuclease activity but retains the ability to specifically bind Holliday junctions.
  • Such mutants include D7N, E66Q, D138N, D141N, D7N, E66D, D138E, and ruvC51, and are described, for example, in Saito A, et al. 1995. Identification of four acidic amino acids that constitute the catalytic center of the RuvC Holliday junction resolvase. Proc Natl Acad Sci U S A 92:7470-4; and Sha ⁇ les GJ, et al. 1993. An E. coli RuvC mutant defective in cleavage of synthetic Holliday junctions. Nucleic Acid Research, 21(15): 3359-64.
  • intra-molecular FRET can be exploited to detect the presence/quantity of Holliday junctions (FIG. 4).
  • the single Holliday junction-binding protein can be double-labeled with two fluorophores, e.g., two GFP mutants that serve as an intra-molecular donor/acceptor FRET pair.
  • the single protein used is RuvC, more preferably one of the aforementioned RuvC mutants.
  • the double- labeled protein undergoes a conformational change upon binding to a Holliday junction, which results in a change in the physical relationship between the two fluorophores and hence a change in FRET signal.
  • the change in FRET can be detected and used as an indicator for the presence and the amount of stable Holliday junctions, as described above for the embodiment that employs two Holliday junction binding proteins.
  • intermolecular FRET can also be exploited to detect the presence/quantity of Holliday junctions if the protein used can form either homo- or hetero-oligomers (FIG. 3).
  • E. coli RuvA exists as a tetramer in solution but can form an octamer upon binding a Holliday junction. Formation of octameric RuvA is dependent on binding a Holliday junction. Therefore, RuvA alone can be used to detect Holliday junctions via inter-molecular FRET.
  • a solid surface can act as the label, such as the surface of an optical biosensors, e.g., Biacore or Iasys.
  • optical biosensors are described, for example, in Canziani G, et al. 1999. Exploring biomolecular recognition using optical biosensors. Methods 19(2): 253-69.
  • a molecule capable of binding a Holliday junction preferably including a protein as discussed above, is immobilized on the surface of the biosensor.
  • the binding of a Holliday junction to the immobilized protein is able to produce a detectable optical signal.
  • the signal can be recorded by the biosensors as an indication of the presence and quantity of stable Holliday junctions.
  • a single label i.e., the biosensor surface
  • the biosensor surface is sufficient for the detection of Holliday junctions.
  • One advantage of this embodiment of the invention is that neither the polynucleotides forming the Holliday junction nor the Holliday junction binding molecules need to be labeled.
  • LOCI Luminescent oxygen channeling immunoassay
  • Luminescent oxygen channeling immunoassay Measurement of particle binding kinetics by chemiluminescence. Proc Natl Acad Sci U S A 91 :5426-30.
  • mass spectrometry is employed to detect a stabilized Holliday junction.
  • One advantage of this embodiment of the invention is that neither the polynucleotides forming the Holliday junction nor the Holliday junction binding molecules need to be labeled. Molecules with higher mass can be generated by either the formation of a four- way Holliday junction from two duplex DNA or the formation of Holliday junction/protein complex(s) upon binding of Holliday junction specifically binding protein(s) to the Holliday junction. Detection of the existence/ratio of molecules with different masses by mass spectrometry can be used to detect/quantitate Holliday junctions and, in turn, to indicate the presence or absence of differences between two DNA fragments. The use of mass spectrometry to characterize macromolecular complexes is described, for example, in Kelleher NL. 2000. From primary structure to function: biological insights from large-molecule mass spectra. Chem Biol. 7(2): R37-45.
  • the mixture that results from subjecting the four-way complexes to branch migration conditions is separated by gel electrophoresis.
  • stabilized Holliday structures can be detected by gel electrophoresis under the appropriate conditions. The presence of a stabilized Holliday structure identified by gel electrophoresis indicates the presence of a difference between the target and reference sequences.
  • the gel electrophoresis conditions should be chosen so that a stabilized Holliday structure can be resolved from other complexes in the mixture such as duplexes, partial duplexes and single stranded polynucleotides.
  • the actual conditions for gel electrophoresis depend on the size and identity of polynucleotide sequences and the partial duplexes. Such conditions will be apparent to those of skill in the art. For instance, when the target and reference sequence are about 35 - 300 bp in length and corresponding partial duplexes are about 50 - 300 bp in length, a stabilized Holliday structure can be resolved in a 4%-6% TBE-PAGE gel at 160V for 30*.
  • a set of PCR primers (Fl, F2, Rl, and R2) can be designed for each SNP position.
  • DNA fragments (partial duplexes) obtained by PCR using the individual's genomic DNA can be regarded as the target DNA.
  • DNA fragments (partial duplexes) of known genotype obtained by using the same set of primers are regarded as the reference DNA. Therefore, there will be two reference DNA (partial duplexes) for each SNP.
  • the target DNA (partial duplex) at each SNP position is mixed and compared with corresponding two versions of reference DNA (partial duplex), one at a time, by undergoing Holliday junction formation branch-migration. After PCR/Branch Migration, the resulting mixtures at multiple (1- millions) SNP positions are pooled together.
  • the pooled DNA is then subjected to conditions (e.g.: gel/capillary electrophoresis, chromotography) that will allow the separation/isolation of Holliday structures.
  • conditions e.g.: gel/capillary electrophoresis, chromotography
  • Holliday junctions can be separated from duplex DNA by gel electrophoresis or capillary electrophoresis. The band containing Holliday junction DNA can then be identified and isolated. DNA from the band containing Holliday junctions can then be eluted/purified from the gel band.
  • the pool comprised of Holliday junctions can be isolated by chromatography.
  • solid surface e.g.: columns, filters, plasticsituated coated/conjugated with a Holliday structure specifically binding protein(s) can be used to isolate/purify Holliday junctions.
  • the existence of DNA fragments of a specific SNP in the purified pool comprised of Holliday junction indicates that the target DNA of that SNP is different from the reference DNA it has been compared with. Or, in other words, the diploid genomic DNA used for generating the target DNA at that specific SNP position has at least one copy of the SNP version that is different from the version of the reference DNA used.
  • a positive hybridization signal for a specific SNP on the chip/microarray means that the diploid genomic DNA used for generating the target DNA at that specific SNP position has at least one copy of the SNP version that is different from the version of the reference DNA used.
  • FIG. 5 a method for genotyping multiple polymo ⁇ hic positions is illustrated in FIG. 5.
  • a target DNA is amplified with four forward primers (F/Rl, F/R2, F/R3 and F/R4) and one reverse primer.
  • the four forward primers F/Rl, F/R2, F/R3 and F/R4 comprise a polynucleotide sequence F that complements the target DNA and one of four tail sequences Tl, T2, T3 and T4.
  • the reverse primer comprises a polynucleotide sequence that complements the target DNA and an optional universal tail UT.
  • PCR is carried out as described above to yield target partial duplexes.
  • the forward and reverse primer are chosen so that the resulting partial duplexes include a polymo ⁇ hism of interest in the target DNA.
  • a reference DNA corresponding to the target DNA and comprising a known sequence at the polymo ⁇ hism is amplified with the same primers to yield reference partial duplexes.
  • the target duplexes and reference duplexes are mixed under conditions in which four-way structures are capable of forming and in which branch migration can occur.
  • Stabilized Holliday structures can be isolated according to any of the methods described above. Isolation of a Holliday structure indicates a difference between the target sequence and the reference sequence.
  • Partial duplexes from each unique target DNA are prepared with a unique set of PCR primers. For instance, with two target DNAs, partial duplexes corresponding to a first target DNA can be prepared with primers that correspond to tails Tl, T2, T3 and T4. Partial duplexes corresponding to a second target DNA can be prepared with primers that correspond to tails T5, T6, T7 and T8. Tails Tl, T2, T3 and T4 should not correspond to tails T5, T6, T7 and T8.
  • Reference partial duplexes for each reference DNA are prepared with primers that correspond to the primers used for the corresponding target DNA.
  • All target partial duplexes can be contacted with corresponding reference partial duplexes in the same mixture, and stabilized Holliday structures can be recovered in one step.
  • the recovered polynucleotides can optionally be amplified by PCR using, for instance, the optional universal tail UT.
  • the recovered polynucleotides can then be identified by techniques known to those of skill in the art. For instance, the recovered polynucleotides can be identified by hybridization with oligonucleotides specific for tails Tl, T2, T3 and T4 or tails T5, T6, T7 and T8.
  • the hybridization can be carried out with, for example, a gene chip, an array of oligonucleotides or labeled beads coated with the oligonucleotides.
  • the presence of a detectable hybridization signal indicates that a particular target DNA differs from its corresponding reference DNA. For instance, hybridization of recovered polynucleotides to oligonucleotides corresponding to tails T5, T6, T7 and T8 indicates that the second target DNA differed from its corresponding reference DNA.
  • the same detection apparatus e.g., gene chip, an array of oligonucleotides or labeled beads coated with the oligonucleotides
  • the detection apparatus is specific for the tails corresponding to the PCR primers used in the above method, not for the target DNA.
  • the present invention provides methods and reagents for resolving four- way complexes on solid substrates.
  • One polynucleotide of a partial duplex corresponding to a polynucleotide sequence is immobilized on a solid support and contacted with other polynucleotides from under conditions in which a four-way complex can form and in which branch migration can occur.
  • the sequence can be, for example, a target sequence which forms a four-way complex with a nucleic acid that corresponds to a reference sequence, or vice versa. If the target sequence and reference sequence are identical, then branch migration goes to completion and one duplex is released from the solid surface.
  • the solid substrate can be any solid substrate known to those of skill in the art.
  • the solid substrate can comprise any material known to those of skill in the art on which a polynucleotide can be immobilized. Suitable materials include, for example, metals, polymers, glasses, polysaccharides, nitrocellulose and the like.
  • the solid substrate may also take on any form including beads, disks, slabs, strips or any other form capable of bearing polynucleotides.
  • the polynucleotides can be bound to the solid substrate by any means known to those of skill in the art for immobilizing molecules.
  • the polynucleotides may be, for example, noncovalently associated with the solid substrate or covalently associated directly or via a linker.
  • the polynucleotides are immobilized on nitrocellulose via ultraviolet cross-linking.
  • each of the two said DNA fragments (A or B) is first linked with either a tail/tag #1 or a tail/tag #2 through PCR amplification (FIGS. 6A and 6B) using one forward primer (F) and either two of the reverse primers (Rl and R2) (FIGS. 6A and 6B).
  • the resulting 4 DNA duplexes are: Al (A + tail/tag #1); A2 (A + tail/tag #2); Bl (B + tail/tag #1); and B2 (B + tail/tag #2).
  • duplexes for example Al
  • the mixture of duplexes A2/B1/B2 is added to immobilized duplex Al followed by branch migration conditions so that partial duplexes A', A", B', B" can form transient Holliday structures (FIGS. 6 A and 6B). If there a mismatch/difference between A and B will the transient Holliday structure become a stabilized Holliday structure/junction (FIG. 6B). When there is no difference between A and B, the transient Holliday structure/junction will resolve into duplexes (FIG. 6A).
  • Any unbound material is then optionally washed from the solid substrate using PCR/Branch migration buffer or any buffer that will not disrupt Holliday structures. Only when there is a mismatch/difference between A and B will stable four- way Holliday structure form on the glass surface that will not be washed away (FIG. 6B).
  • Reagents are then added to the solid substrate that can not only specifically bind to Holliday structure but can also be detected directly or indirectly.
  • Said reagents include but not limited to GFP (or other fluorescence) labeled Holliday-junction-specifically-binding proteins such as RuvC, RuvA, RusA and their homologues, and other such reagents described in detail above. Any reagents not specifically bound to the surface are then optionally washed. The specifically bound reagent(s) are then detected and/or quantitated by methods appropriate for the reagent. Such methods are described in detail above. Specifically bound reagents indicate the presence of a stabilized Holliday structure on the solid substrate and thereby a difference between A and B.
  • Any genetic variation, including SNPs, involves at least two possible versions for each variable position within a DNA sequence. To determine which versions a target DNA sample (either diploid or haploid) has at a particular variable position, the target DNA sequence(s) are compared with each reference DNA sequences representing all possible versions of variations at that variable position. It is known that DNA variations exist in forms other than SNPs. Not only can this invention detect SNPs, but also, polymo ⁇ hisms involving multiple bases, multi-base-paired deletions, insertions and mis-sense mutations.
  • genotyping by means of SNPs will be used to illustrate, and not limit, an application of this invention to determine the genotypes of various genetic variations of diploid individuals, such as humans.
  • the target DNA is amplified from the genomic DNA in question.
  • two reference DNA (A or B) is amplified from either two reference genomic DNA samples (A/A or B B) or from cloned DNA fragments containing the two reference DNA sequences (A or B). All three DNA samples are amplified by PCR with two common sets of unlabeled primers under standard PCR conditions.
  • LF is preferably ⁇ 10bp away from the SNP position.
  • LR1 and LR2 share the same 3 '-end portion (LR) that hybridizes to the target sequence at the right side of the SNP position in question.
  • LR1/LR2 is designed in such a way that it should be at minimum distance from the SNP position in question as far as the feasibility of the PCR amplification is concerned.
  • the 3' end of LR1/LR2 preferably corresponds to the base pair next to the SNP position in question.
  • RF hybridizes to the target sequence at the left side of the SNP position in question.
  • RF is designed in such a way that it should be at minimum distance from the SNP position in question as far as the feasibility of the PCR amplification is concerned.
  • the 3' end of RF preferably corresponds to the base pair next to the SNP position in question.
  • LR1 and LR2 share the same 3 '-end portion (RR) that hybridizes to the target sequence at the right side of the SNP position in question.
  • RR1/RR2 is designed in such a way that it should be at minimum distance from the SNP position in question as far as the feasibility of the PCR amplification is concerned.
  • the 3' end of RR1/RR2 should generally be between 5 and 500 bps, and preferably less than 10 bp.
  • Amplicon L(X/X) is mixed separately at 1 :1 ratio with amplicon L(A/A) and amplicon L(B/B) to form mixture L(X/X)/(A/A) and L(X/X)/(B/B).
  • Amplicon R(X/X) is mixed separately at 1 : 1 ratio with amplicon R(A/A) and amplicon R(B/B) to form mixture R(X/X)/(A/A) and R(X/X)/(B/B).
  • the resulting four mixtures - L(X/X)/(A/A), L(X/X)/(B/B), R(X/X)/(A A) and R(X/X)/(B B) - are then denatured/re-annealed and subjected to branch migration conditions ( 95°C for 2 min, followed by 65°C 30' in PCR buffer with Mg++.)
  • the presence and amount of stable Holliday junctions are then detected using Holliday junction specifically binding protein(s) as described earlier.
  • the detected signals of the four mixtures are recorded and compared with the bar codes for all possible genotypes (FIG. 7 and Table 1) to determine the genotype of the target genomic DNA sample at the SNP position in question.
  • This invention will not only allow the determination of the genotype of the target genomic DNA sample at the SNP position in question but will also determine the presence and location of other mutation(s) in the vicinity of the SNP in question.
  • Holliday structures can be formed from polynucleotides with differing sequences.
  • the stabilized Holliday structures can be detected by gel electrophoresis according to the methods of the present invention.
  • Five regions of human genomic DNA that contain known single-nucleotide polymo ⁇ hisms (SNPs) were PCR-amplified using tailed reverse primers to allow the formation of Holliday junctions.
  • the sequence of these regions, the location and identity of the respective SNPs within them and the sequences of the primers can be found in the National Center for Biotechnology Information (NCBI) SNP database.
  • NCBI assay LD's of the SNPs used were as follows: 4215, 4217, 4213, 4141 and 4212.
  • Genomic DNA samples from the M08PDR panel (the smallest subset of the Human Polymo ⁇ hism Discovery Resource panel containing eight individual DNA samples) were purchased from Coriell Cell Repository (Camden, NJ). Two genomic DNA samples were amplified for each SNP, one homozygote and one heterozygote. The genotypes of these samples are described in Lishanski, 2000, Clinical Chemistry 46 (9), 1464-1470.
  • the primer sequences for amplifying genomic DNA were as follows.
  • Rt2 5'- GATCCTAGGCCTCACGTATTGTAAACTTTCTGAGCCTCTGG -3 ' (SEQ ID NO: 3)
  • Rtl 5 '- ACCATGCTCGAGATTACGAGGGTTTGCTGGAAGAAAGCAG -3 ' (SEQ ID NO: 5)
  • Rt2 5'- GATCCTAGGCCTCACGTATTGGTTTGCTGGAAGAAAGCAG -3' (SEQ LD NO: 6)
  • Rt2 5'- GATCCTAGGCCTCACGTATTCTGAATACTCTCCATCCTTGCC -3 ' (SEQ ID NO: 9)
  • Rtl 5'- ACCATGCTCGAGATTACGAGGGGGTCTCTGCAGTTAACCA -3' (SEQ ID NO: 11)
  • Rt2 5'- GATCCTAGGCCTCACGTATTGGGGTCTCTGCAGTTAACCA -3 ' (SEQ ID NO: 12)
  • Rtl 5'- ACCATGCTCGAGATTACGAGAATATGCAAAGTAATTTTCTGGCC -3 ' (SEQ LD NO: 14)
  • Rt2 5'- GATCCTAGGCCTCACGTATTAATATGCAAAGTAATTTTCTGGCC -3 ' (SEQ LD NO: 15) where F is the forward PCR primer, R is the reverse PCR primer, tl and t2 are the "tail" sequences (underlined) that are common for all 5 amplicons.
  • the forward and reverse primer sequences are published in NCBI SNP database.
  • PCR amplifications were carried out using a PTC-200 DNA Engine thermocycler (MJ Research Inc., Waltham, MA). 35 PCR cycles were performed with 10 s denaturation at 94°C, 15 s reannealing at 62°C and 45 s extension at 72°C. The cycling was preceded by a 10-min incubation at 95°C to activate AmpliTaq GoldTM DNA polymerase (Applied Biosystems, Foster City, CA) and followed by 2 min of denaturation at 95°C and 30-min incubation at 65°C (reannealing and branch migration).
  • the reaction mixtures (100 ⁇ l) contained 100 ng genomic DNA, 2.5 U AmpliTaq GoldTM DNA polymerase, 200 ⁇ M each dNTP and 250 nM each primer in the commercial AmpliTaq buffer (10 mM Tris-HCl, pH 8.3, 50 mM KC1, 1.5 mM MgCl 2 , 0.01 % gelatin).
  • FIG. 8A shows a typical gel picture.
  • a 4-12% gradient pre-cast gel was run in 1 X
  • the relatively faint slowly moving bands are present only in the samples heterozygous for each SNP, when there is a single-base sequence difference between the two alleles. Slower bands correspond to longer amplicons.
  • a serial dilution experiment (not shown) demonstrated that the amount of DNA in these bands is approximately equal to the expected amount of unresolved Holliday junctions (1/16 of the total material).
  • the slowly moving bands disappear upon digestion with the wild type E.coli RuvC protein that is a Holliday junction-specific endonuclease (not shown). Based on this evidence, the slowly moving band clearly represents the unresolved Holliday junctions and is, therefore, indicative of the presence of two alternative alleles in genomic DNA.
  • RuvA and RuvC proteins are part of the multi-subunit RuvABC complex that promotes homologous genetic recombination by resolving Holliday junctions. Shinagawa and Iwasaki, 1996 Trends In Biological Sciences 21, 107-111; Eggleston and West, 2000, J.Biol.Chem. 275, 26467-26476. Their binding to synthetic Holliday junctions in vitro is well studied. Davies and West, 1998, Current Biology 8, 725-727; Whitby et al., ! 1996, LMoLBiol. 264, 878-890.
  • the 22kDa RuvA protein exists in solution as a homotetramer and binds specifically to synthetic Holliday junctions either as a tetramer or an octamer, depending on the protein concentration.
  • the 19 kDa RuvC protein is a Holliday junction-specific endonuclease or a resolvase that binds to Holliday junctions as a dimer, cleaves them and initiates their resolution.
  • Several mutants of RuvC protein have been isolated that retain their specific binding activity but lack the endonuclease activity. Saito et al., 1995, Biochemistry 92, 7470-7474.
  • Recombinant Ruv A and RuvC (D7N mutant) proteins that were expressed and purified from E.coli were provided by Dr. Hideo Shinagawa (Osaka University, Japan).
  • PCR amplification and branch migration of selected samples from M08PDR panel were conducted as described in Example 1.
  • SNPs 3989 and 4216 two more SNPs were included in the experiments: SNPs 3989 and 4216.
  • the following sets of primers were used: SNP 3989
  • Rtl 5'- ACCATGCTCGAGATTACGAGT ⁇ GGCTTTCATCTTCCCC-3' (SEQ ID NO: 17)
  • Rt2 5'- GATCCTAGGCCTCACGTAT rrTGGCTTTCATCTTCCCC -3 ' (SEQ JD NO: 18)
  • Rtl 5'- ACCATGCTCGAGATTACGAGATGTTTTATGTGGAGAGGTATCTGC -3 ' (SEQ ID NO: 20)
  • Rt2 5'- GATCCTAGGCCTCACGTAT ⁇ ATGTTTTATGTGGAGAGGTATCTGC -3 ' (SEQ ID NO: 21)
  • FIG. 9B shows the binding of RuvA under the conditions that ensure its specificity towards Holliday junctions for four PCR products that correspond to four different SNPs.
  • the experimental conditions were identical to those of FIG. 9A, above. Only heterozygous samples were used in this binding experiment.
  • the Holliday junction band underwent a change in electrophoretic mobility upon RuvA binding (- indicates no RuvA and + indicates RuvA added).
  • FIG. 9C provides yet another example of RuvA, mutant RuvC and the mixture of these two proteins binding to Holliday junctions for three PCR products that correspond to three different SNPs in a heterozygous form.
  • the experimental conditions were identical to those of FIG. 9A, above, except that the gel was run for 75 min and stained with SYBR Gold.
  • RuvC was demonstrated by probing the Holliday structure with antisera against the two proteins (provided by Dr. Hideo Shinagawa, Osaka University, Japan).
  • Electrophoretic transfer of proteins from this gel onto a nitrocellulose membrane was conducted using an Xcell IITM Blot Module (Invitrogen Co ⁇ ., San Diego, CA) at 20 V for 2 hr.
  • the transfer buffer was 12 mM Tris base- 96 mM Glycine (pH 8.3), 20% Methanol.
  • the membrane was briefly rinsed in 1 X TBST buffer (Roche Molecular Biochemicals,
  • the membrane was incubated in 10 ml of 1 : 1000 dilution of hnmunoPureTM goat anti-rabbit IgG (alkaline phosphatase conjugate) in 1% blocking solution for 30 min. The membrane was again washed in four 20 ml changes of 1 X TBST, 5-10 min each wash.
  • the substrate solution for alkaline phosphatase was prepared by adding 44 ⁇ l of 75 mg/ml Nitroblue Tetrazolium Chloride (NBT) and 33 ⁇ l of 5-Bromo-4- chloro-3-indolylphosphate p-Toluidine Salt (BCLP) to 10 ml of 0.1 M Tris-HCl, pH 9.5, 0.1
  • Lane 1 provides heterozygous PCR product + RuvA
  • This Example describes methods of detecting a stabilized Holliday structure by detecting the intermolecular interaction of two molecules with specificity for a Holliday structure.
  • This Example makes use of the homogeneous chemiluminescent detection method LOCI (Ullman et al., 1994, Proc.Nat.Acad.Sci.USA 91,5426-5430; Packard BioScience, Meriden, CT). It makes use of the fact that when two particles, a donor and an acceptor, are in close proximity by virtue of a biological interaction, chemiluminescence is produced.
  • PCR products are prepared from a reference sequence and a target sequence as described in Examples 1-3. The PCR products are contacted under conditions in which four-stranded complexes can form and in which branch migration can occur.
  • This example deomonstrates that two molecules of the same protein can be individually labeled with different labels and used for the detection of differences between a target polynucleotide and a reference polynucleotide.
  • RuvA protein exists as a tetramer in solution and two such tetramers bind Holliday junctions to form an octamer.
  • One RuvA tetramer is labeled in vitro with biotin (b-RuvA) and another tetramer is labeled with fluorescein (f-RuvA).
  • the labeled RuvA molecules can be used to detect stabilized Holliday structures.
  • PCR products are prepared as described in Examples 1-4 and subject to branch migration conditions. Stabilized Holliday structures, if any, are contacted with b-RuvA and f-RuvA. The resulting mixture is then contacted with donor beads coated with streptavidin and acceptor beads coated with anti-fluorescein antibody. The interaction of the donor beads and acceptor beads is detected as described in Example ⁇ 4. The presence of a donor-acceptor signal indicates a difference between the target sequence and the reference sequence.
  • FRET pairs other pairs of molecules that specifically interact with a Holliday are labeled with FRET pairs.
  • RuvA and mutant RuvC are labeled with two different fluorescent dyes that constitute a FRET pair, and their assembly on Holliday junctions is detected.
  • the donor and acceptor fluorophores are introduced into RuvA * by fusing RuvA molecules with two different mutants of GFP (Heim, 1999, in Methods in Enzymology 302,408-423; Green Fluorescent Protein). Nectors for cloning and expression of such fusions are available from Aurora Bioscience (San Diego, CA). This approach eliminates the necessity to chemically modify the protein. Alternatively, RuvA and mutant RuvC are fused to two different GFP mutants and their assembly on Holliday junctions detected.
  • This example provides another sensitive and efficient method for detecting differenences between polynucleotide sequences.
  • the method in this Example is based on Bioluminescence Resonance Energy Transfer (BRET; Packard BioScience, Meriden CT).
  • BRET Bioluminescence Resonance Energy Transfer
  • energy transfer from a bioluminescent donor luciferase to an acceptor GFP is detected.
  • the donor fluorophore After binding, the donor fluorophore is excited with an appropriate wavelength using a spectrofluorometer and BRET is detected by the appearance of sensitized fluorescence of the acceptor. No excitation light source is required for the detection of the BRET signal. The presence of the BRET signal indicates a difference between the polynucleotide sequences.
  • RuvA and mutant RuvC can be fused to luciferase and GFP, respectively (or vice versa), and their assembly on Holliday junctions detected by BRET.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des méthodes permettant de détecter la présence ou l'absence d'une différence entre deux séquences d'acides nucléiques apparentées. Lesdites méthodes consistent à mettre en contact un acide nucléique cible et un acide nucléique de référence dans des conditions où ils peuvent former un complexe d'acide nucléique à quatre branches possédant une structure susceptible de migrations. Dans ces conditions de contact, si l'acide nucléique de référence et l'acide nucléique cible sont identiques, la migration entre les branches peut s'effectuer jusqu'à son terme et résulter en un échange de brins complet. Si l'acide nucléique de référence et l'acide nucléique cible sont différents, la migration entre les branches n'arrive pas à son terme, ce qui entraîne la création d'un complexe à quatre branches stable. Pour identifier la présence d'une différence entre les acides nucléiques, on utilise ledit complexe à quatre branches stable. Ledit complexe à quatre branches stable peut également être détecté à l'aide de molécules se liant spécifiquement à ces complexes, soit par électrophorèse sur gel soit par isolement spécifique du complexe à quatre branches stable.
PCT/US2001/007858 2000-03-11 2001-03-12 Methodes de detection des differences entre acides nucleiques WO2001069200A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002402483A CA2402483A1 (fr) 2000-03-11 2001-03-12 Methodes de detection des differences entre acides nucleiques
JP2001568034A JP2003527119A (ja) 2000-03-11 2001-03-12 核酸の差の検出方法
AU4563401A AU4563401A (en) 2000-03-11 2001-03-12 Methods for detection of differences in nucleic acids
EP01918574A EP1266202A4 (fr) 2000-03-11 2001-03-12 Methodes de detection des differences entre acides nucleiques
AU2001245634A AU2001245634B2 (en) 2000-03-11 2001-03-12 Methods for detection of differences in nucleic acids

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US18866900P 2000-03-11 2000-03-11
US60/188,669 2000-03-11
US22888500P 2000-08-29 2000-08-29
US60/228,885 2000-08-29
US23422900P 2000-09-21 2000-09-21
US60/234,229 2000-09-21
US23436300P 2000-09-22 2000-09-22
US60/234,363 2000-09-22
US24284000P 2000-10-23 2000-10-23
US24277000P 2000-10-23 2000-10-23
US60/242,770 2000-10-23
US60/242,840 2000-10-23

Publications (2)

Publication Number Publication Date
WO2001069200A2 true WO2001069200A2 (fr) 2001-09-20
WO2001069200A3 WO2001069200A3 (fr) 2002-03-14

Family

ID=27558796

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/007858 WO2001069200A2 (fr) 2000-03-11 2001-03-12 Methodes de detection des differences entre acides nucleiques

Country Status (6)

Country Link
EP (1) EP1266202A4 (fr)
JP (1) JP2003527119A (fr)
CN (1) CN1191374C (fr)
AU (2) AU4563401A (fr)
CA (1) CA2402483A1 (fr)
WO (1) WO2001069200A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2241640A1 (fr) * 2008-01-22 2010-10-20 Hiroshima University Procédé et kit de dosage de protéine de liaison à l'acide nucléique

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997023646A1 (fr) * 1995-12-22 1997-07-03 Behringwerke Aktiengesellschaft Detection de differences dans les acides nucleiques
US5698400A (en) * 1994-04-25 1997-12-16 Avitech Diagnostics, Inc. Detection of mutation by resolvase cleavage
US5824471A (en) * 1995-06-05 1998-10-20 Brigham And Women's Hospital Detection of mismatches by cleavage of nucleic acid heteroduplexes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2117599A (en) * 1998-01-20 1999-08-02 Mayo Foundation For Medical Education And Research Simplified mutation detection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698400A (en) * 1994-04-25 1997-12-16 Avitech Diagnostics, Inc. Detection of mutation by resolvase cleavage
US5824471A (en) * 1995-06-05 1998-10-20 Brigham And Women's Hospital Detection of mismatches by cleavage of nucleic acid heteroduplexes
WO1997023646A1 (fr) * 1995-12-22 1997-07-03 Behringwerke Aktiengesellschaft Detection de differences dans les acides nucleiques
US6013439A (en) * 1995-12-22 2000-01-11 Dade Behring Marburg Gmbh Detection of differences in nucleic acids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1266202A2 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2241640A1 (fr) * 2008-01-22 2010-10-20 Hiroshima University Procédé et kit de dosage de protéine de liaison à l'acide nucléique
EP2241640A4 (fr) * 2008-01-22 2012-10-31 Univ Hiroshima Procédé et kit de dosage de protéine de liaison à l'acide nucléique

Also Published As

Publication number Publication date
EP1266202A2 (fr) 2002-12-18
CA2402483A1 (fr) 2001-09-20
CN1429277A (zh) 2003-07-09
EP1266202A4 (fr) 2005-11-09
WO2001069200A3 (fr) 2002-03-14
CN1191374C (zh) 2005-03-02
AU2001245634B2 (en) 2005-10-06
AU4563401A (en) 2001-09-24
JP2003527119A (ja) 2003-09-16

Similar Documents

Publication Publication Date Title
US6653079B2 (en) Methods for detection of differences in nucleic acids
EP1427847B1 (fr) Methodes et compositions de generation de copies multiples de sequences d'acides nucleiques et methodes de detection correspondantes
US6815164B2 (en) Methods and probes for detection and/or quantification of nucleic acid sequences
US6830884B1 (en) Method of amplification
US7371580B2 (en) Use of unstructured nucleic acids in assaying nucleic acid molecules
US20080051568A1 (en) Capture moieties for nucleic acids and uses thereof
US9617587B1 (en) Isothermal amplification components and processes
CA2725405A1 (fr) Procedes et dosages pour la capture d'acide nucleiques
EP1151136A1 (fr) Methode pour detecter des nucleotides alleliques par amplification multiplex arms
US20100112556A1 (en) Method for sample analysis using q probes
Liu et al. A novel single nucleotide polymorphism detection of a double-stranded DNA target by a ribonucleotide-carrying molecular beacon and thermostable RNase HII
US6821733B2 (en) Methods and compositions for detecting differences between nucleic acids
CA2394800A1 (fr) Procede d'amplification d'une sonde d'acide nucleique circularisee
US20070148636A1 (en) Method, compositions and kits for preparation of nucleic acids
AU2001245634B2 (en) Methods for detection of differences in nucleic acids
US20030235827A1 (en) Methods and compositions for monitoring primer extension and polymorphism detection reactions
US20040235004A1 (en) Methods for detection of differences in nucleic acids
AU2001245634A1 (en) Methods for detection of differences in nucleic acids
US6878530B2 (en) Methods for detecting polymorphisms in nucleic acids
US20030129598A1 (en) Methods for detection of differences in nucleic acids
Buzdin DNA hybridization in solution for Mutation Detection
WO2002024960A1 (fr) Detection de la variation d'adn

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2402483

Country of ref document: CA

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2001 568034

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001245634

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001918574

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 018093108

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001918574

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2001245634

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2001918574

Country of ref document: EP